Joint Formulary & PAD

Quetiapine - Schizophrenia and other psychoses

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Immediate release tablets
Associated Icons :
SPC
Restrictions / Comments :
Important
Preferred

Initiation and stabilisation by a Mental Health specialist for a minimum of 1 month before any request for transfer of prescribing responsibility.

 

Status 2

Red
Formulations :
  • Modified release tablets
Associated Icons :
R
SPC
Restrictions / Comments :
Important

Modified release tablets are reserved for use when immediate release tablets are not suitable.

Modified release quetiapine MAY be continued in Primary Care (after a 1-month period of stabilisation by a Mental Health specialist) where the use of immediate release tablets would risk destabilising the patient.

PAD Profile

ChemicalSubstance :
Quetiapine
Indication :
Schizophrenia and other psychoses
Group Name :
Keywords :
Brand Names Include :
Important Information :

 

 

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3
Traffic Light Entries :
2

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the length of prescribing of anti-psychotics by the specialist team at Surrey & Borders Partnership NHS Foundation Trust as:

Mental Health specialist initiation and prescribing for at least 1 month and until the patient is stabilised on treatment prior to transfer of care to primary care.

Where a stabilised patient requires a simple, non-complex and non-urgent dose adjustment, this can be managed in primary care on recommendation by the specialist team.

Immediate release (IR) quetiapine should be used in preference to the XL formulations as recommended by the PCN in May 2012.

Quetiapine IR should be prescribed generically. The Seroquel brand was assigned a BLACK traffic light status by the PCN in May 2017

SABP have updated (Jan 2018) a number of resources aimed at supporting the use of IR quetiapine in preference to the XL formulations - see below

Where quetiapine is used in Behavioural and Psychological Symptoms of Dementia (BPSD), please see separate entry Quetiapine - Behavioural and Psychological Symptoms of Dementia - surrey.res.services